Strategic Acquisition NovelCath is now part of Cirtec Medical, signaling strong integration potential for the combined Interventional Device business. This presents immediate cross-sell opportunities for Cirtec’s design, development, vertical integration, and full-device assembly services to NovelCath’s existing customers and programs.

Minimally Invasive Focus Specialization in minimally invasive interventional delivery systems (Structural Heart, Electrophysiology, Neurovascular) aligns with high-demand sectors. Sales outreach can target device manufacturers and healthcare providers seeking end-to-end catheter delivery system design and manufacturing.

In-House Capabilities In-house extrusion, braiding, coiling, and assembly capabilities within NovelCath enable rapid prototyping and shorter time-to-market. Position Cirtec’s vertical integration as a value add for prospects requiring controlled supply chains and reduced third-party risk.

Financial Scope Reported revenue of 1M to 10M indicates a smaller but growing organization with potential for expansion through strategic programs, product line extensions, and expanded manufacturing capacity under Cirtec’s scale and resources.

Tech & Compliance Existing tech stack featuring AWS, security and deployment practices (HSTS, reCAPTCHA, ALB) and modern web tools suggests a mature development environment. This can be leveraged to discuss scalable, secure cloud-enabled design and manufacturing data workflows for complex medical devices.